A World Health Organization (WHO) committee said on July 12 that human genome editing technologies to treat serious disease should be shared more generously, to allow poorer nations to benefit from the highly dynamic scientific field.
The summit of the Group of Seven industrialized nations in southwest England saw global leaders pledging at least 1 billion Covid-19 vaccines for underdeveloped countries and struggling nations.
The United States on June 10 raised the pressure on other Group of Seven (G7) leaders to share their vaccine hoards to bring an end to the pandemic by pledging to donate 500 million doses of the Pfizer coronavirus vaccine to the world’s poorest countries.
The Biden administration plans to donate 500 million Pfizer coronavirus vaccine doses to nearly 100 countries over the next two years, three sources familiar with the matter told Reuters on June 9.
COVAX will deliver 237 million doses of AstraZeneca’s Covid-19 shot to 142 countries by the end of May as the World Health Organization-backed program steps up the global roll-out of its vaccine supplies.
The United States under President Joe Biden intends to join the COVAX vaccine facility that aims to deliver coronavirus vaccines to poor countries, his chief medical adviser, Anthony Fauci, told the World Health Organization (WHO).
Eli Lilly and Co. entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of the company’s experimental antibody treatments for Covid-19 to low and middle-income countries.
Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
AstraZeneca announced plans to manufacture 2 billion doses of the University of Oxford’s COVID-19 vaccine, AZD122.